ASC-J9

• CAT Number: I003914
• CAS Number: 52328-98-0
• Molecular Formula: C23H24O6
• Molecular Weight: 396.4
• Purity: ≥95%
• Synonyms: (1E,4Z,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one
• Target: Androgen Receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• InChI: InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-15,24H,1-4H3/b9-5+,10-6+,18-15-
• InChIKey: ZMGUKFHHNQMKJI-CIOHCNBKSA-N
• SMILES: COC1=CC=C(/C=C/C(/C=C(O)/C=C/C2=CC(OC)=C(OC)C=C2)=O)C=C1OC

ASC-J9(CAT: I003914) is a synthetic compound that is being studied for its potential use in treating prostate cancer. It works by selectively degrading the androgen receptor (AR) protein, which plays a crucial role in the growth and survival of prostate cancer cells. By degrading the AR protein, ASC-J9 is able to inhibit the growth of prostate cancer cells and induce apoptosis (cell death). Studies have shown that ASC-J9 is effective against prostate cancer cells that have become resistant to other therapies, making it a promising candidate for the development of new treatments for advanced prostate cancer. Additionally, ASC-J9 has been shown to have minimal side effects, further supporting its potential use as a treatment option.

Reference

1:Targeting androgen receptor with ASC-J9 attenuates cardiac injury and dysfunction in experimental autoimmune myocarditis by reducing M1-like macrophage. Ma W, Wang Y, Lu S, Yan L, Hu F, Wang Z.Biochem Biophys Res Commun. 2017 Apr 15;485(4):746-752. doi: 10.1016/j.bbrc.2017.02.123. Epub 2017 Feb 27. PMID: 28246012 2:Correction: ASC-J9 Suppresses Renal Cell Carcinoma Progression by Targeting an Androgen Receptor-Dependent HIF2a/VEGF Signaling Pathway. [No authors listed]Cancer Res. 2016 Oct 1;76(19):5908. No abstract available. PMID: 27698191 3:Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals. Xu J, Lin H, Li G, Sun Y, Shi L, Ma WL, Chen J, Cai X, Chang C.Int J Cancer. 2017 Feb 1;140(3):705-717. doi: 10.1002/ijc.30446. Epub 2016 Nov 9. PMID: 27668844 Free PMC Article4:New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals. Lin SJ, Chou FJ, Lin CY, Chang HC, Yeh S, Chang C.Oncotarget. 2016 Oct 11;7(41):66769-66775. doi: 10.18632/oncotarget.11484. PMID: 27564257 Free PMC Article5:ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.Cancer Lett. 2016 Aug 28;379(1):154-60. doi: 10.1016/j.canlet.2016.05.018. Epub 2016 May 24. PMID: 27233475 6:ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals. Wen S, Tian J, Niu Y, Li L, Yeh S, Chang C.Cancer Lett. 2016 Jul 1;376(2):377-86. doi: 10.1016/j.canlet.2016.01.057. Epub 2016 Apr 1. PMID: 27045473 7:Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, Li Y, Chou F, Chang C.Mol Carcinog. 2016 Dec;55(12):2278-2290. doi: 10.1002/mc.22468. Epub 2016 Feb 19. PMID: 26894509 8:Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression. Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C.Mol Cancer Ther. 2015 Nov;14(11):2586-94. doi: 10.1158/1535-7163.MCT-14-1055-T. Epub 2015 Aug 11. PMID: 26264279 Free PMC Article9:[ASC-J9 for castration-resistant prostate cancer]. Yamashita S, Arai Y.Nihon Rinsho. 2014 Dec;72(12):2126-9. Japanese. PMID: 25518345 10:Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells. Verderio P, Pandolfi L, Mazzucchelli S, Marinozzi MR, Vanna R, Gramatica F, Corsi F, Colombo M, Morasso C, Prosperi D.Mol Pharm. 2014 Aug 4;11(8):2864-75. doi: 10.1021/mp500222k. Epub 2014 Jul 18. PMID: 24945469